Filing Flows › Heron Therapeutics (HRTX) › Q2 2026
Heron Therapeutics (HRTX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 10, 2026
Heron Therapeutics (HRTX) reported revenue of $37.7M for the second quarter 2026 (Q2 2026), +1% from a year earlier and +9% from the quarter before. Operating margin was -5.4%, net loss $5.5M (14.6% of revenue).
Heron Therapeutics, Q2 2026: revenue $37.7M (+1% year over year), operating margin -5.4%, net loss $5.5M, operating cash flow −$2.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $37.7M | +9% | +1% |
| Operating profit | −$2.0M | — | — |
| Net earnings | −$5.5M | — | — |
| Operating cash flow | −$2.2M | — | — |
What changed
Revenue was $37.7M in Q2 2026, up 1% year over year and up 9% from the previous quarter. CINVANTI was the largest line at 58% of revenue. ZYNRELEF added $2.9M year over year (up 35%), 615% of the total change. SUSTOL declined 78%.
Gross margin was 69.3%, down 4.2 points from Q2 2025. Operating costs exceeded revenue by $2.0M, an operating margin of -5.4%. Operating expenses fell 3% while revenue rose 1%. The fastest-growing cost line was Sales & marketing (+22%). The quarter ended with a net loss of $5.5M, narrower than the previous quarter's $8.1M loss. Net interest and other expense of $3.4M was the main reason.
Operating cash flow was −$2.2M. Non-cash charges added back $452K of depreciation and amortization and $3.2M of share-based compensation. Working capital and other items used $354K. Capital expenditures of $138K exceeded it, leaving free cash flow of −$2.4M.
Questions
What was Heron Therapeutics' revenue in the second quarter 2026?
Heron Therapeutics (HRTX) reported revenue of $37.7M for the second quarter 2026 (Q2 2026), +1% from a year earlier and +9% from the quarter before.
Was Heron Therapeutics profitable in the second quarter 2026?
Operating loss was $2.0M (-5.4% of revenue) and net loss $5.5M.
Source: Heron Therapeutics 10-Q on SEC EDGAR.